International Research Collaboration Aims to Personalise Prevention and Treatment of Cardiovascular Diseases
MAASTRICHT, Netherlands, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The international public-private research consortium iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) has launched to better understand cardiovascular disease and optimise future prevention and treatment. The consortium brings together 33 leading international partners from civil society, academia and industry, and is led and coordinated by Maastricht University and global healthcare company Novo Nordisk.
- 33 leading international partners, supported by the Innovative Health Initiative (IHI), have teamed up to launch the research consortium iCARE4CVD to better understand cardiovascular disease and optimise future prevention and treatment.
- MAASTRICHT, Netherlands, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The international public-private research consortium iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) has launched to better understand cardiovascular disease and optimise future prevention and treatment.
- The consortium brings together 33 leading international partners from civil society, academia and industry, and is led and coordinated by Maastricht University and global healthcare company Novo Nordisk.
- Our mission however, within iCARE4CVD, is to personalise diagnosis and management of CVD to improve both outcome and patient satisfaction.